341 related articles for article (PubMed ID: 24160374)
1. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
Spinks J; Chen G; Donovan L
Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
[TBL] [Abstract][Full Text] [Related]
2. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
3. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
McManus P; Birkett DJ; Dudley J; Stevens A
Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
[TBL] [Abstract][Full Text] [Related]
5. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
6. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
7. [The effect of generic price competition on drug consumption and health insurance pharmaceutical expenditures in Hungary].
Répásy B; Endrei D; Zemplényi A; Agoston I; Hornyák L; Nagy Z; Csákvári T; Vajda R; Boncz Imre
Acta Pharm Hung; 2015; 85(3):83-8. PubMed ID: 26642646
[TBL] [Abstract][Full Text] [Related]
8. Some drugs more equal than others: pseudo-generics and commercial practice.
Probyn AJ
Aust Health Rev; 2004 Nov; 28(2):207-17. PubMed ID: 15527401
[TBL] [Abstract][Full Text] [Related]
9. Generic drugs: international trends and policy developments in Australia.
Lofgren H
Aust Health Rev; 2004; 27(1):39-48. PubMed ID: 15362295
[TBL] [Abstract][Full Text] [Related]
10. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
Kong Y
Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
[TBL] [Abstract][Full Text] [Related]
11. Do generics offer significant savings to the UK National Health Service?
Kanavos P
Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
[TBL] [Abstract][Full Text] [Related]
12. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
Vacca C; Acosta A; Rodriguez I
Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
[TBL] [Abstract][Full Text] [Related]
13. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Pavenik N
Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
[TBL] [Abstract][Full Text] [Related]
14. Rising cost of anticancer drugs in Australia.
Karikios DJ; Schofield D; Salkeld G; Mann KP; Trotman J; Stockler MR
Intern Med J; 2014 May; 44(5):458-63. PubMed ID: 24612257
[TBL] [Abstract][Full Text] [Related]
15. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
16. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
17. [Price differences between generic and innovator medicines in Brazil].
Vieira FS; Zucchi P
Rev Saude Publica; 2006 Jun; 40(3):444-9. PubMed ID: 16810368
[TBL] [Abstract][Full Text] [Related]
18. Generic script share and the price of brand-name drugs: the role of consumer choice.
Rizzo JA; Zeckhauser R
Int J Health Care Finance Econ; 2009 Sep; 9(3):291-316. PubMed ID: 19130220
[TBL] [Abstract][Full Text] [Related]
19. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
[TBL] [Abstract][Full Text] [Related]
20. Price and welfare effects of a pharmaceutical substitution reform.
Granlund D
J Health Econ; 2010 Dec; 29(6):856-65. PubMed ID: 20832130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
